Myotonic Dystrophy Type 1 (DM1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Myotonic Dystrophy Type 1 (DM1) Market Outlook
Thelansis’s “Myotonic Dystrophy Type 1
(DM1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Myotonic Dystrophy Type 1 (DM1) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Myotonic
Dystrophy Type 1 (DM1) Overview
Myotonic
Dystrophy Type 1 (DM1) is a multisystemic, autosomal dominant disorder caused
by an unstable expansion of a CTG trinucleotide repeat in the 3′ untranslated
region of the DMPK gene on chromosome 19q13.3, which encodes the dystrophia
myotonica protein kinase. The condition affects skeletal and smooth muscle, as
well as ocular, cardiac, endocrine, and central nervous systems, with clinical
severity and age of onset correlating with repeat length. DM1 is typically
categorized into three phenotypes—mild, classic, and congenital—each with
distinct features ranging from cataracts and mild myotonia to profound
hypotonia, respiratory compromise, and developmental delay in congenital cases.
Diagnosis is confirmed via molecular genetic testing, especially in individuals
presenting with distal muscle weakness, myotonia, and systemic involvement.
Despite ongoing research, there are currently no FDA-approved therapies
specifically targeting DM1, and management remains symptomatic and
multidisciplinary.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment